Automated Insulin Delivery for Type 1 Diabetes

This trial explores how automated insulin delivery (AID) systems can help manage Type 1 diabetes in children. The researchers aim to determine if early use of these systems can improve blood sugar control and simplify life for patients. Participants will use a Tandem Automated Insulin Delivery System, which includes an insulin pump, and will share their experiences through surveys. This trial is ideal for those diagnosed with Type 1 diabetes in the last two weeks who plan to receive care at Stanford Children's Pediatric Diabetes Clinic. As an unphased trial, it offers a unique opportunity to contribute to groundbreaking research that could simplify diabetes management for children.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the Tandem Automated Insulin Delivery System is safe for people with type 1 diabetes. One study found that the Tandem t:slim X2 insulin pump, a component of this system, is safe for young children, suggesting it is likely safe for other age groups as well. Another review found that the Tandem Mobi system enhances users' quality of life and is well-received. Overall, this system predicts blood sugar levels and automatically adjusts insulin delivery, simplifying and improving the safety of diabetes management.¹²³⁴⁵

Researchers are excited about the Tandem Automated Insulin Delivery System for Type 1 Diabetes because it offers a more personalized approach to managing blood sugar levels. Unlike traditional insulin pumps, this system automatically adjusts insulin delivery based on real-time glucose readings, potentially reducing the burden of constant monitoring. This hands-free feature could lead to improved blood sugar control and a better quality of life for users. Additionally, the ability for users to choose between devices like the Tandem Mobi or Tandem X2 provides flexibility to match individual needs and preferences.

Research has shown that the Tandem Automated Insulin Delivery System, which includes the Tandem Mobi and t:slim X2 pumps, effectively manages type 1 diabetes. In this trial, participants will choose either the Tandem Mobi or Tandem X2 pump to begin early pump usage. Studies have found that these devices control blood sugar by predicting glucose levels 30 minutes in advance and automatically adjusting insulin delivery. Users have reported spending more time with their blood sugar in a healthy range and experiencing lower hemoglobin A1c levels, which measure average blood sugar over time. The system also maintains low rates of hypoglycemia (very low blood sugar) from the first day of use. Overall, the Tandem system simplifies and enhances diabetes management.¹²⁵⁶⁷